Overview
Alzheimer's Disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia, the decline in cognitive functioning which affects one in 10 people over the age of 65, and one in three people over 85. Trial treatments are aimed at temporarily relieving symptoms and slowing the rate of decline. Research has shown that medications, lifestyle choices, and therapies can all improve symptoms, slow disease progression and improve quality of life for Alzheimer's patients. Clinical trials are an important part of the process of finding and developing new treatments. By participating in clinical trials, Alzheimer's patients and their families in the medical community can help create a better future for themselves and others.
Research published in this journal
3 peer-reviewed articles, ranked by relevance. Each links to its DOI.
Early Prediction of Alzheimer’s Disease Using OCT Imaging Technique
JALR. New Journal, Old questions, Fresh insights
How this research is being cited
The 3 articles above have been cited 5 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2026 · BMC Geriatrics
-
P. Borodi et al. · 2024 · Romanian Journal of Ophthalmology
-
2022 · Metabolic Brain Disease
-
2022 · Metabolic Brain Disease
-
Gerard Martí-Juan et al. · 2020 · Human Brain Mapping
A sample of recent works citing this journal's research on Alzheimer's Disease Trial, linking to each citing work.